Topic is suspended
| Status | Suspended |
| Decision | Selected |
| Process | TA |
| ID number | 1527 |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 March 2021 | For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 05 March 2021 | Suspended. Topic is suspended |
| 20 May 2019 | Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
| 02 May 2019 | In progress. Referred on 27 June 2018 |
For further information on our processes and methods, please see our CHTE processes and methods manual